MarketCapExport financials
Boston Scientific Corporation (BSX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Boston Scientific Corporation Financial Ratios 2025-2006 | BSX
Brief overview of Boston Scientific Corporation's market valuation
The review covers five available annual periods spanning 2021 to 2025.
Market valuation is represented by P/E 39.05x (median 60.16x), EV/EBITDA 25.22x (median 25.93x), P/S 5.63x (median 5.63x). The multiple basket looks neutral against its history, differing from median levels by roughly -2.7%.
Earnings yield calculated as 1/P/E is about 2.6%, showing current profit per unit of share price.
Capital efficiency is characterized by ROE 11.9%, ROA 6.6%, ROCE 14.9%. Capital returns look adequate and support overall financial resilience.
Current PEG of 0.98x shows no clear imbalance between price and expected earnings momentum.
The cash conversion cycle increased 25.7 days to 107 days, weakening working-capital efficiency.
What the ratios show
Boston Scientific Corporation's multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
39.0 | 84.0 | 60.2 | 96.5 | 58.6 | -612.3 | 12.9 | 30.9 | 369.3 | 93.3 | -98.4 | -164.8 | -150.3 | -2.5 | 20.5 | -8.5 | -14.0 | -9.6 | -47.1 | - |
P/S |
5.6 | 9.3 | 6.7 | 5.3 | 5.1 | 5.1 | 5.6 | 5.3 | 4.2 | 3.9 | 3.1 | 2.7 | 2.5 | 1.4 | 1.2 | - | - | - | - | - |
EPS |
2.0 | 1.3 | 1.1 | 0.5 | 0.7 | -0.1 | 3.4 | 1.2 | 0.1 | 0.3 | -0.2 | -0.1 | -0.1 | -2.9 | 0.3 | -0.7 | -0.7 | -1.4 | -0.3 | - |
EV (Enterprise Value) |
111 B | 155 B | 94.9 B | 66.4 B | 59.1 B | 48.5 B | 76.9 B | 63.8 B | 50.2 B | 43.5 B | 35 B | 29.6 B | 28 B | 20.4 B | 18.7 B | 8.85 B | 13.5 B | 18 B | 21.9 B | -1.67 B |
EBITDA per Share |
3.36 | 2.63 | 2.44 | 1.95 | 1.61 | 0.74 | 1.75 | 1.64 | 1.53 | 1.37 | 1.11 | 1.01 | 0.965 | 0.943 | 1.42 | 0.11 | -0.04 | -0.43 | 0.61 | - |
EV/EBITDA |
22.3 | 39.9 | 26.8 | 23.9 | 25.2 | 39.1 | 28.8 | 25.9 | 20.9 | 20.2 | 19.4 | 17.4 | 17.2 | 10.8 | 6.1 | 55.3 | -225.6 | -28.1 | 24.2 | - |
PEG |
0.98 | 3.69 | 2.66 | 5.08 | 3.44 | 369.93 | 0.07 | 0.02 | -5.22 | 0.38 | 0.98 | -1050.47 | -1.55 | 0.0 | 0.14 | - | - | - | - | - |
P/B |
2.6 | 3.9 | 2.7 | 2.1 | 1.9 | 1.6 | 4.4 | 5.9 | 5.5 | 4.8 | 3.7 | 3.0 | 2.8 | 1.5 | 0.8 | 0.4 | 0.6 | 0.7 | - | - |
P/CF |
24.9 | 45.1 | 38.3 | 44.2 | 32.6 | 33.3 | 43.9 | -8612.8 | 34.7 | 54.3 | 66.6 | 19.4 | 21.7 | 9.9 | 12.8 | 27.9 | 17.2 | 16.2 | 25.0 | - |
ROE % |
11.93 | 8.48 | 8.26 | 3.97 | 6.26 | -0.54 | 33.87 | 19.15 | 1.48 | 5.15 | -3.78 | -1.84 | -1.85 | -59.21 | 3.88 | -9.43 | -8.33 | -15.45 | - | - |
ROA % |
6.62 | 4.69 | 4.53 | 2.15 | 3.23 | -0.27 | 15.38 | 7.96 | 0.55 | 1.92 | -1.32 | -0.70 | -0.73 | -23.71 | 2.07 | -4.81 | -4.07 | -7.50 | - | - |
ROCE % |
14.91 | 11.96 | 12.15 | 9.38 | 7.21 | -0.52 | 6.77 | 10.54 | 11.44 | 9.09 | 6.30 | 6.35 | 5.99 | 6.05 | 8.82 | -5.81 | -7.27 | -11.42 | - | - |
Current Ratio |
- | - | - | - | - | - | 1.0 | 0.8 | 0.7 | 0.9 | 1.4 | 1.3 | 1.7 | 1.7 | 1.7 | - | - | - | - | - |
DSO |
- | - | - | - | - | - | 65.7 | 59.7 | 62.4 | 64.1 | 62.2 | 58.5 | 66.8 | 61.3 | 59.7 | - | - | - | - | - |
DIO |
168.8 | 183.8 | 182.8 | 160.4 | 145.6 | 154.3 | 185.0 | 151.3 | 151.7 | 143.8 | 170.7 | 156.2 | 150.6 | 137.4 | 127.8 | 125.3 | 123.6 | 63.1 | - | - |
DPO |
61.7 | 66.0 | 75.8 | 76.4 | 64.3 | 55.6 | 63.5 | 45.3 | 74.6 | 67.3 | 35.1 | 43.3 | 41.3 | 36.0 | 27.9 | 27.8 | 32.0 | 17.7 | - | - |
Operating Cycle |
168.8 | 183.8 | 182.8 | 160.4 | 145.6 | 154.3 | 250.7 | 211.0 | 214.2 | 207.9 | 232.9 | 214.7 | 217.4 | 198.6 | 187.5 | 125.3 | 123.6 | 63.0 | - | - |
Cash Conversion Cycle |
107.0 | 117.8 | 107.0 | 84.0 | 81.3 | 98.8 | 187.2 | 165.8 | 139.6 | 140.6 | 197.8 | 171.5 | 176.1 | 162.6 | 159.6 | 97.5 | 91.6 | 45.4 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Boston Scientific Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.62 | 0.9 | 0.51 | 0.54 | 0.46 | 0.32 | 0.22 | 0.34 | 0.34 | 0.18 | 0.21 | - | 0.12 | 0.17 | 0.07 | - | 0.28 | 0.12 | 0.23 | - | -0.12 | -0.11 | 0.01 | - | 0.09 | 0.11 | 0.31 | - | 0.31 | 0.4 | 0.22 | - | 0.21 | 0.11 | 0.21 | - | 0.17 | -0.15 | 0.15 | - | -0.15 | 0.08 | - | - | 0.03 | - | 0.1 | - | - | 0.1 | -0.26 | - | -0.48 | -2.51 | 0.08 | - | 0.09 | 0.1 | 0.03 | 0.13 | 0.06 | -1.05 | -0.06 | 0.1 |
EBITDA per Share |
1.28 | 0.98 | 0.79 | 0.63 | 0.84 | 0.57 | 0.42 | 0.67 | 0.54 | 0.42 | 0.58 | - | 0.31 | 0.35 | 0.52 | - | 0.84 | 0.24 | 0.45 | - | 0.44 | 0.34 | 0.3 | - | 0.33 | 0.33 | 0.44 | - | 0.33 | 0.33 | 0.35 | - | 0.33 | 0.21 | 0.31 | - | 0.31 | -0.2 | 0.26 | - | -0.17 | 0.21 | 0.07 | - | 0.1 | - | 0.2 | - | 0.13 | 0.21 | -0.2 | - | -0.38 | -2.47 | 0.18 | - | 0.16 | 0.2 | 0.26 | 0.31 | 0.2 | -0.9 | 0.12 | 0.27 |
ROE % |
15.58 | 14.98 | 12.06 | 10.41 | 9.31 | 8.95 | 8.18 | 8.35 | 6.97 | 5.81 | 4.99 | 3.23 | 5.78 | 5.88 | 6.54 | 5.88 | 4.87 | 1.37 | 0.27 | -1.90 | -0.99 | 1.13 | 5.14 | 5.07 | 10.02 | 15.48 | 17.78 | 14.73 | 18.76 | 15.89 | 13.67 | 10.25 | 13.64 | 6.53 | 7.45 | 3.31 | 0.18 | -1.59 | 1.47 | -1.53 | -0.87 | 2.33 | 2.77 | 2.79 | 2.71 | 4.03 | -1.44 | -3.50 | -13.17 | -65.17 | -65.52 | -60.10 | -58.85 | -47.90 | 4.59 | 2.94 | 4.66 | 4.31 | -11.71 | -12.82 | -13.37 | -14.74 | -0.71 | 1.18 |
ROA % |
8.70 | 8.37 | 6.58 | 5.68 | 5.12 | 4.92 | 4.50 | 4.58 | 3.83 | 2.69 | 3.20 | 2.24 | 2.84 | 2.25 | 3.35 | 3.01 | 2.51 | 0.72 | 0.16 | -0.95 | -0.53 | 0.47 | 2.34 | 2.30 | 4.36 | 6.59 | 7.51 | 6.12 | 7.61 | 6.32 | 5.19 | 3.78 | 5.04 | 2.41 | 2.76 | 1.23 | 0.14 | -0.56 | 0.58 | -0.53 | -0.28 | 0.83 | 1.05 | 1.06 | 1.03 | 1.56 | -0.60 | -1.38 | -5.25 | -26.08 | -26.21 | -24.07 | -23.40 | -18.85 | 2.23 | 1.57 | 2.41 | 2.17 | -5.47 | -6.04 | -6.28 | -6.95 | -0.36 | 0.60 |
ROCE % |
17.12 | 16.54 | 15.82 | 13.89 | 13.59 | 13.11 | 12.39 | 12.93 | 11.61 | 10.39 | 10.36 | 7.27 | 9.62 | 9.23 | 9.13 | 6.35 | 5.01 | 2.20 | 1.51 | -0.85 | 1.91 | 6.02 | 10.38 | 9.43 | 13.87 | 15.60 | 17.50 | 13.60 | 18.98 | 17.74 | 18.44 | 13.78 | 18.94 | 8.61 | 9.75 | 4.56 | -0.17 | -1.87 | 3.47 | -0.89 | 0.11 | 3.77 | 3.35 | 2.97 | 4.55 | 6.92 | 2.94 | -0.11 | -8.75 | -62.54 | -63.05 | -58.01 | -56.47 | -45.74 | 9.31 | 6.46 | 8.73 | 9.32 | -6.55 | -9.01 | -9.23 | -13.78 | 0.38 | 2.05 |
DIO |
181.8 | 173.3 | 173.2 | 159.7 | 176.5 | 186.4 | 185.7 | 187.4 | 192.9 | 185.4 | 171.8 | - | 83.3 | 78.3 | 159.8 | - | 153.8 | 137.0 | 140.8 | - | 141.9 | 155.8 | 165.9 | - | 185.4 | 190.1 | 171.6 | - | 158.3 | 144.0 | 152.3 | - | 154.4 | 155.6 | 142.7 | - | 146.7 | 136.4 | 156.9 | - | 172.0 | 171.7 | 172.2 | - | 156.9 | 153.3 | 156.6 | - | 160.5 | 154.4 | 140.6 | - | 144.6 | 139.6 | 131.2 | - | 124.9 | 123.5 | 134.1 | 132.4 | 125.0 | 127.2 | 132.0 | - |
DPO |
67.9 | 61.5 | 58.8 | 54.8 | 60.0 | 63.0 | 65.6 | 69.8 | 75.8 | 76.2 | 75.9 | - | 37.4 | 31.4 | 71.2 | - | 69.1 | 63.0 | 57.6 | - | 53.9 | 59.2 | 59.7 | - | 63.6 | 65.2 | 55.7 | - | 47.4 | 43.1 | 59.7 | - | 75.9 | 76.5 | 68.6 | - | 68.7 | 63.8 | 52.2 | - | 35.4 | 35.3 | 41.3 | - | 43.5 | 42.5 | 43.2 | - | 44.0 | 42.4 | 37.7 | - | 37.9 | 36.6 | 31.4 | - | 27.2 | 26.9 | 28.8 | 27.5 | 28.7 | 31.4 | 31.8 | - |
Operating Cycle |
- | - | 173.2 | 159.7 | 176.5 | 186.4 | 185.7 | 187.4 | 192.9 | 185.4 | 171.8 | - | 83.3 | 78.3 | 159.8 | - | 153.8 | 137.0 | 140.8 | - | 141.9 | 155.8 | 165.9 | - | 185.4 | 190.1 | 171.6 | - | 158.3 | 144.0 | 152.3 | - | 154.4 | 155.6 | 142.7 | - | 146.7 | 136.4 | 156.9 | - | 172.0 | 171.7 | 172.2 | - | 156.9 | 153.3 | 156.6 | - | 160.5 | 154.4 | 140.6 | - | 144.6 | 139.6 | 131.2 | - | 124.9 | 123.5 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 114.4 | 104.9 | 116.5 | 123.4 | 120.1 | 117.6 | 117.1 | 109.2 | 95.9 | - | 45.9 | 46.9 | 88.7 | - | 84.7 | 74.0 | 83.2 | - | 88.0 | 96.7 | 106.1 | - | 121.8 | 124.8 | 115.9 | - | 110.9 | 100.9 | 92.7 | - | 78.5 | 79.1 | 74.1 | - | 78.0 | 72.5 | 104.7 | - | 136.6 | 136.4 | 130.8 | - | 113.5 | 110.9 | 113.4 | - | 116.5 | 112.1 | 102.8 | - | 106.6 | 102.9 | 99.8 | - | 97.7 | 96.6 | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Boston Scientific Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Curacao
USA
Israel
Britain
Canada
Costa-rica
